AnaptysBio director trims stake by 31.26%
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
AnaptysBio (NASDAQ:ANAB) director Hollings Renton sold 5,000 shares for $249,350, cutting his holdings by 31.26%. The transaction was executed under a Rule 10b5-1 trading plan. The sale follows quarterly earnings of $5.11 per share, which beat estimates, and revenue of $27.49 million, also above expectations. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $77.79, while shares trade near $48.53.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.